doi: 10.1161/01.ATV.0000232583.51472.73
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Editorials |
Clopidogrel Pharmacogenetics
Promising Steps Towards Patient Care?
From the Department of Medicine, Cardiovascular Division (A.L.B.), and the Division of Oncology and Departments of Genetics and Molecular Biology and Pharmacology (H.L.M.), Washington University School of Medicine, St. Louis, Mo.
Correspondence to Amber L. Beitelshees, PharmD, MPH, Washington University School of Medicine, 660 S Euclid Ave, Box 8086, St. Louis, MO 63110. E-mail abeitels{at}im.wustl.edu
Clopidogrel is a pro-drug that requires oxidation to its active metabolite, 2-oxoclopidogrel, by CYP3A4 and other CYP enzymes. This active thiol metabolite inhibits adenosine diphosphate (ADP)-induced platelet aggregation by blocking the platelet P2Y12 receptor (Figure), resulting in 
50% reduction in ADP-mediated platelet aggregation. Clopidogrel is standard of care in many patients undergoing percutaneous coronary intervention (PCI) and those experiencing acute coronary syndromes. However, it has been suggested that response to clopidogrel varies widely with nonresponse rates ranging from 4% to 30% at 24 hours.1,2 Suggested mechanisms for this variability have included under-dosing, drug interactions with CYP3A4 substrates and inhibitors,3 and intrinsic interindividual differences resulting from genetic polymorphisms in the pathways of clopidogrel pharmacokinetics and pharmacodynamics.
|
See page 1895
In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Angiolillo and colleagues report on the influence of CYP3A4 genotype on interpatient variability in clopidogrel responsiveness.4 The authors find that an intronic single nucleotide polymorphism (SNP) in the CYP3A4 gene, IVS10+12G>A (also called CYP3A4*1G), influences platelet reactivity ex vivo as measured by glycoprotein IIb/IIIa receptor activation in response to clopidogrel in a group of patients with stable coronary disease on established clopidogrel and aspirin therapy. Additionally, they replicated these findings in a group of clopidogrel naïve patients undergoing elective coronary stent placement treated with a 300 mg loading dose of the drug. Ex vivo platelet aggregation profiles in response to clopidogrel did not differ by CYP3A4 genotype.
This study represents the first pharmacogenetic study (ie, genotype–response association) to focus on candidate genes involved in clopidogrel pharmacokinetics. Other investigators have reported on the influence of phenotypic variability in CYP3A4 activity (measured by erythromycin breath test) on clopidogrel-induced inhibition of platelet aggregation, supporting the notion that genetic influences on metabolism may be important.3 Clopidogrel pharmacogenetics studies to date have evaluated pharmacodynamic candidate genes including the P2Y12 and P2Y1 receptors, the glycoprotein Ia and IIIa receptor subunit genes, and the protease-activated receptor-1 (PAR-1).5–11 These studies have yielded primarily neutral findings5–7,10 with the following exceptions. First, studies evaluating the platelet glycoprotein (GP) Ia gene (ITGA2) have found that among patients on dual therapy with aspirin and clopidogrel, carriers of the 807 T variant allele have increased platelet aggregation compared with 807 C/C individuals.8,9 Additionally, although studies evaluating the association of P2Y12 polymorphisms and clopidogrel-induced platelet aggregation have been neutral, Ziegler et al evaluated the effect of two exonic SNPs in P2Y12, 34C>T and 53G>T, on the occurrence of recurrent neurological events in patients with peripheral arterial disease with significant results.12 They found that in patients treated with clopidogrel, 34T carriers had a 4-fold increased risk of ischemic stroke and/or carotid revascularization compared with 34 C/C individuals.12 Ex vivo platelet aggregation or reactivity was not measured. The relative contribution of CYP3A4 genotype was not evaluated in these studies.
The cytochrome P450 3A (CYP3A) family of proteins metabolizes half of currently available drugs approved by the Food and Drug Administration. Therefore, polymorphisms in this gene family could play an important role in variability in medication response. However, CYP3A4 is unique from many other polymorphic drug metabolizing enzymes (such as CYP2D6 and CYP2C9) in that, until recently,13 no null allele had been identified to cause lack of protein formation. The allele that has been identified resulting in nonfunctional protein, CYP3A4*20, is extremely rare.13 Additionally, expression of CYP3A4 displays a unimodal distribution, with many rare variants contributing to small changes in protein function. With the exception of CYP3A4*1B, no CYP3A4 variant has been consistently associated with a clinical phenotype or with altered CYP3A4 expression and even the CYP3A4*1B allele has not been consistently associated with altered expression.14 In addition to the IVS10+12G>A SNP (CYP3A4*1G), Angiolillo et al also evaluated the IVS7+258A>G and IVS7+894C>T SNPs and did not find any of them to influence response to clopidogrel. They did not evaluate CYP3A4*1B or CYP3A4*3 because of the infrequent occurrence in their patient population.
Although not evaluated in the present study, CYP3A5 should be investigated as a high priority candidate gene in clopidogrel response. Unlike CYP3A4, CYP3A5 does have polymorphisms resulting in dramatic functional consequences. And, although CYP3A5 protein is present in a greater proportion of African Americans (55%), it is still present in 25% of Whites, and perhaps even more frequently among Spanish-Europeans.15 Interestingly, in the present study, the IVS10+12G>A SNP was in linkage disequilibrium (LD) with CYP3A4*1B, which has been reported to be in strong LD with CYP3A5*1 (which results in increased protein expression).16 Furthermore, according to HapMap data in the CEPH Whites, IVS10+12G>A and CYP3A5*1 are in LD with a D' of 0.86, which could be a mechanistic contributor to the increased clopidogrel efficacy seen in CYP3A4 IVS10+12G>A variant carriers.
The only paper (published in abstract form) evaluating CYP3A5 genotype and clopidogrel response to date focused on platelet aggregation, which Angiolillo and colleagues have suggested may not be the optimal phenotype in evaluating responsiveness to clopidogrel.17
Several key issues regarding so-called "clopidogrel resistance" must be resolved to determine how large of an impact the findings from the present study will have on patient care. First, the relationship between variability in platelet responsiveness to clopidogrel and thrombotic events has only been demonstrated in a small observational study of 60 patients with ST-elevation myocardial infarction undergoing PCI.18 Therefore, the clinical relevance of clopidogrel resistance is still a matter of debate. Second, the cut points used in this analysis for considering clopidogrel non-response or low response have been used widely in the literature, but are not based on any data supporting their relation to clinical events and likely vary depending on the clinical indication for clopidogrel. Third, the optimal measure of response to clopidogrel remains to be determined. It remains unclear whether the measurement of platelet aggregation or platelet reactivity is most reflective of clopidogrel response and the assays used to measure these responses as well as the timing of measurement can result in varying response rates. Last, new PDY12 antagonists are in development which may be associated with lower non-response rates.19 If these agents are approved, they may provide more effective therapeutic alternatives to clopidogrel. Whether the same pharmacogenetic associations seen with clopidogrel will hold true with these agents is not known. If the non-response rates to these new agents are indeed on the order of 10-fold lower than those of clopidogrel as initially reported,19 clinically important pharmacogenetic associations may be overcome by this improved efficacy.
An interesting area of opportunity for clopidogrel pharmacogenetics involves the recently published CHARISMA trial, in which dual therapy with aspirin and clopidogrel was not beneficial in a group of high risk patients with vascular disease or multiple risk factors.20 Furthermore, the dual therapy was associated with a "concerning trend" toward an increased risk of bleeding. It is likely that subgroups of patients could be identified using pharmacogenetics to identify those patients most likely to derive benefit from dual therapy, without putting the larger population of patients at risk of severe adverse events. As an important step toward this end, Angiolillo and colleagues provide a provocative report of an association with an intronic SNP in the CYP3A4 gene and platelet activity in response to clopidogrel. Future studies evaluating whether this polymorphism and those in CYP3A5 predict adverse clinical outcomes in clopidogrel-treated individuals, as well as those determining the functional basis for this association are eagerly awaited.
 |
Acknowledgments |
|---|
We thank Dr Issam Zineh for his helpful comments and assistance with the figure.
Source of Funding
The authors are supported in part by NIH SCCOR (P50HL077113).
Disclosures
None.
|
References |
|---|
 Top References |
|---|
1. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908–2913.
2. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 2003; 145: 239–247.[CrossRef][Medline] [Order article via Infotrieve]
3. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107: 32–37.
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006; 26; 1895–1900.[CrossRef][Medline] [Order article via Infotrieve]
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005; 116: 491–497.[CrossRef][Medline] [Order article via Infotrieve]
6. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol. 2006; 47: 541–546.
7. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y and GP IIIa and response to aspirin and clopidogrel. Thromb Res. In press.
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol. 2005; 96: 1095–1099.[CrossRef][Medline] [Order article via Infotrieve]
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, Hernandez-Antolin R, Sabate M, Trabetti E, Pignatti PF, Macaya C. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis. 2004; 15: 427–433.[CrossRef][Medline] [Order article via Infotrieve]
10. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005; 16: 199–204.[Medline] [Order article via Infotrieve]
11. Smith SM, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, Storey RF. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets. 2005; 16: 340–345.[CrossRef][Medline] [Order article via Infotrieve]
12. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, Sabeti S, Amighi J, Minar E, Brunner M, Muller M, Mannhalter C. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005; 36: 1394–1399.
13. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M, von Richter O. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther. 2006; 79: 339–349.[CrossRef][Medline] [Order article via Infotrieve]
14. Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K, Brockmoller J, Nurnberg P, Zanger UM, Wojnowski L. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics. 2006; 16: 59–71.[Medline] [Order article via Infotrieve]
15. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit. 2005; 27: 819–821.[CrossRef][Medline] [Order article via Infotrieve]
16. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, Koch I, Klattig J, Zanger U, Brockmoller J. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 2002; 94: 630–631;author reply 631–632.
17. Smith SMG JH, Peters G, Wilmington, Armstrong M, Fontana P, Gaussem P, Storey RF. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain variability in the inhibitory effects of clopidogrel therapy. Eur Heart J. 2005; 26: P2963.
18. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171–3175.
19. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27: 1166–1173.
20. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706–1717.
Related Article:
Arterioscler. Thromb. Vasc. Biol. 2006 26: 1895-1900.
This article has been cited by other articles:
 |
|
 |
|
  G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O'Donoghue and S. D. Wiviott Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? Circulation, November 28, 2006; 114(22): e600 - e606. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||